GLOW (BPC-157 / GHK-Cu / TB-500): What It Is, Where to Get It Prescribed, and What It Costs

GLOW is not a single molecule. It is three independently studied peptides — GHK-Cu, BPC-157 and TB-500 — dissolved together in one sterile multi-dose vial by a compounding pharmacy. Each has its own research literature, its own described mechanism and its own regulatory file at the FDA. The name is a brand name for the combination; it does not appear in any journal, and "does GLOW work" has to be broken into three questions because the combination itself has never been studied as a combination.

The rationale prescribers give is that tissue repair runs in overlapping phases — cell migration, new blood-vessel growth, matrix synthesis, remodelling — and each component is described in the research as acting on a different phase: BPC-157 on blood supply and cell migration, TB-500 on cell motility, GHK-Cu on collagen and matrix. Combining them covers the sequence with one injection rather than three.

The proportions are worth noticing. GHK-Cu is 50 of the 70 mg in the vial, so by mass GLOW is mostly a GHK-Cu preparation with two smaller repair components alongside it, which is why it is positioned toward skin and connective tissue as much as toward injury. The ratio is fixed by the pharmacy's formulation and cannot be adjusted per component, which is the genuine trade-off of any blend.

It is not a painkiller and has no described analgesic mechanism. It is not a treatment for a structural problem — a full-thickness tendon rupture, a displaced fracture or a locking joint is a surgical or imaging question, and no peptide changes that. It is not a hormone, a steroid or a growth-hormone secretagogue. It is not a topical: the human GHK-Cu skin literature is mostly creams, and GLOW is an injection. And it is not a shortcut around rehabilitation.

GHK-Cu is a tripeptide — glycine, histidine, lysine — that binds copper with high affinity. It occurs naturally in human plasma, where its concentration is reported to decline with age. The copper-carrying role is the basis for most of its described effects, because collagen cross-linking, elastin formation and several antioxidant enzymes are copper-dependent.

In cell and animal work, and in reviews in Biomed Research International (2015) and the International Journal of Molecular Sciences (2018), GHK-Cu is described as increasing synthesis of collagen, elastin, proteoglycans and glycosaminoglycans, and as shifting the balance between matrix metalloproteinases, which break tissue down, and their inhibitors. Gene-expression work reports effects across a large number of genes rather than one pathway. It is also described as supporting angiogenesis, and as having antioxidant, anti-inflammatory and hair-follicle activity, in those models.

BPC-157 is a fifteen-amino-acid partial sequence of a protein originally isolated from human gastric juice. Animal work describes it activating the VEGFR2 receptor and downstream nitric-oxide signalling, which is the axis the body uses to grow new blood vessels into healing tissue. A 2011 paper in the Journal of Applied Physiology, working with rat Achilles tendon explants and cultured tendon fibroblasts, reported greater tendon outgrowth, better cell survival under oxidative stress and faster cell migration with BPC-157, and traced the migration effect to the FAK–paxillin pathway that governs how cells attach and move. Related cell work reports higher growth hormone receptor expression in tendon fibroblasts — a finding often misread, since it describes making those cells more responsive to growth hormone already present, not raising growth hormone.

Separately, the largest body of BPC-157 research concerns protection of the gastrointestinal lining in animal models, which is where the compound was first identified. A fuller treatment is on the BPC-157 page.

TB-500 is a synthetic peptide reproducing the actin-binding segment of thymosin beta-4, a 43-amino-acid protein that is one of the most abundant inside many human cells. The FDA's 2026 briefing document identifies TB-500 as the seven-residue stretch from positions 17 to 23 of the parent protein, with an acetyl group on the first amino acid. Thymosin beta-4's primary described function is binding actin monomers, the protein that gives a cell its shape and lets it move.

The consequence described in the research is cell migration: repair cells moving into a wound. A 1999 paper in the Journal of Investigative Dermatology reported faster wound closure and increased cell migration with thymosin beta-4 in rats and in cultured human cells; a 2005 review in Trends in Molecular Medicine and a 2012 review in Expert Opinion on Biological Therapy summarise the wider literature across dermal, cardiac and corneal models, including described effects on angiogenesis, inflammatory mediators and laminin-5. One point of precision matters here: almost all of that literature concerns the full-length protein. TB-500, the fragment, is assumed to share the mechanism because it is the actin-binding segment; the direct evidence for the fragment itself is much thinner, and the FDA's briefing document noted it could not find animal wound-healing studies of the fragment on its own. A fuller treatment is on the TB-500 page.

The repair-phase map below is the clinical rationale for the blend. It is a rationale, not a finding — no study has confirmed that the three act in sequence when injected together.

What is not on that map is a dedicated inflammation component. That gap is the whole difference between GLOW and KLOW, which adds KPV for exactly that phase.

GHK-Cu has the deepest literature of the three and is the only component with human studies of any size. The human work is mostly small studies of topical GHK-Cu on facial skin — reporting changes in firmness, fine lines and elasticity — and observational wound-healing reports, summarised in the 2015 and 2018 reviews above. None of the human studies used the injectable form.

This rests on BPC-157 and, by extension from thymosin beta-4, on TB-500. A 2003 paper in the Journal of Orthopaedic Research examined transected Achilles tendon in rats and reported faster reattachment and better functional recovery in treated animals; the 2011 Journal of Applied Physiology work above supplies the cell-level story. Animal models of muscle crush injury report faster functional recovery, measured as time to weight-bearing and force production. For TB-500, the tendon and muscle case is inferred from the full-length protein's wound-healing work rather than shown directly.

This is BPC-157 alone: animal work describing protection against NSAID- and alcohol-induced gastric damage and improvement in inflammatory bowel models. Neither GHK-Cu nor TB-500 adds to that case, which is why a gut complaint is usually a reason to consider BPC-157 on its own rather than GLOW.

This is the honest part, and the part worth understanding before starting.

There are no randomised controlled trials of GLOW, or of any three-peptide combination of these components, in humans. The blend has never been studied as a blend. Evidence is per component, and it is uneven:

• GHK-Cu has small human studies, mostly of topical application to skin, plus observational wound-healing reports. There are no randomised controlled trials of injectable GHK-Cu.
• BPC-157 has early-phase human work for inflammatory bowel indications and substantial prescribing experience. The one randomised, placebo-controlled human study the FDA identified for its July 2026 briefing was a meeting abstract of a two-week enema trial in 53 people with ulcerative colitis, which the agency considered too incompletely reported to draw conclusions from. There are no randomised controlled trials in humans for tendon or soft-tissue injury, and none of the injectable route.
• TB-500 has no human trials of any kind; the FDA's briefing document found no published report of the fragment being given to patients for any condition. The full-length thymosin beta-4 protein has been studied in early-phase human trials for chronic dermal wounds and corneal conditions, reviewed in the 2012 paper above, but those used the whole protein, not the fragment.

Much of medicine rests on mechanism plus clinical experience, and that is the basis physicians prescribe GLOW on. But the accurate framing is "described in preclinical research and used clinically," not "proven in people."

• That three peptides together do more than any one alone. No study has compared the blend with its components.
• That injected GHK-Cu does for skin what topical GHK-Cu is reported to do.
• An effect size for any indication, because those trials have not been run.
• A timeline in humans. Timelines given by prescribers are clinical experience, not trial endpoints.
• Long-term safety over years of continuous use, which is part of why a physician reviews each refill.
• Efficacy for any condition as an FDA-approved treatment. Neither GLOW nor any component is approved for anything.

Between 2023 and early 2026, BPC-157, TB-500 and injectable GHK-Cu all sat in Category 2 of the FDA's 503A bulk drug substances list — the category for substances the agency had flagged as presenting significant safety risks. On 15 April 2026 the FDA gave notice that it would remove twelve peptides from Category 2 about a week later, because the nominations behind them had been withdrawn, and BPC-157, TB-500 and injectable GHK-Cu were all among them. GHK-Cu's non-injectable listing, which had sat in Category 1, was withdrawn at the same time.

Removal from Category 2 lifts the safety-risk designation. It does not, by itself, place a substance on the positive 503A Bulks List; that requires an advisory committee review and a final FDA determination. The FDA took the substances to its committee anyway, "electing to proceed" despite the withdrawn nominations.

The FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 and took up BPC-157 (reviewed for ulcerative colitis) and TB-500 (reviewed for wound healing) on the first day, each as the free base and the acetate. FDA's own scientists proposed against inclusion for both, citing incomplete characterisation, absent safety data and insufficient evidence of effectiveness. The committee voted the other way: 8–6 with one abstention to recommend adding BPC-157, and 8–6 with one abstention to recommend adding TB-500, to the 503A Bulks List.

A committee vote is a recommendation, not a decision. The FDA issues its own determination through notice-and-comment rulemaking, and that determination is still pending as of September 2026.

GHK-Cu was not on the July agenda. The FDA has said the committee will consider it, along with several other April removals, at a meeting to be held before the end of February 2027. Until then it is where the other two were between April and July: no longer flagged, not yet reviewed for the positive list.

None of the three components is restricted; two have been formally recommended for the positive list and await final FDA action; the third is scheduled for review. None is an FDA-approved drug product, and compounded medications never are — they are prepared by a licensed pharmacy to a physician's prescription, not approved as manufactured products.

Most people notice little or nothing beyond injection-site tenderness. Some describe a background ache in a problem area settling, but noticing nothing in this window is normal and is not a sign the course is not working.

This is where prescribers most often describe a reduced background ache in the affected area and, for those tracking skin, a sense of better hydration. It is the window one vial covers on a weekday schedule.

Where tissue-level change happens, this is where it would be expected to show, based on the animal timelines for the tendon and soft-tissue work. Prescribers describe it as improved tolerance to loading. It typically takes a second vial to reach.

Skin turnover is slow, and GHK-Cu's described effects on collagen and matrix are slow by nature; prescribers who use GLOW with skin quality as a goal describe texture and tone changes, where they occur, as a two-month-plus proposition. After a course there is no withdrawal and no rebound described for any component; whether any benefit persists depends on whether the underlying tissue actually changed.

The directions are written in millilitres and in insulin-syringe units because that is what you can actually read off the barrel. 0.25 mL is 25 units on a U-100 syringe; the number is printed on your medication. Because the three are in fixed proportion, every dose delivers the same split: 2.5 mg GHK-Cu, 0.5 mg BPC-157 and 0.5 mg TB-500. If your directions and syringe markings appear to disagree, ask before dosing.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. Some prescribers direct injection near the affected area on the theory that local concentration matters; others do not, because the mechanisms described are systemic. Your directions will say.

20 doses at five per week is four weeks of weekday dosing, which is why refills run on a 28-day cycle. Weekends off is part of the schedule, not a missed dose. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating runs from first puncture and is on the label; a multi-peptide vial is not something to keep past it.

The only difference is KPV. KLOW is the same three repair peptides at the same amounts plus 10 mg of KPV, a tripeptide fragment of alpha-MSH described in animal and cell work as an anti-inflammatory signal. If persistent inflammation is part of your picture, KLOW is the fuller formula; if it is not, GLOW covers the repair case with one fewer component.

The two-peptide stack is the injury-only version. It omits GHK-Cu, which is the skin and matrix component and the majority of GLOW by mass. For a single tendon or ligament problem it is the more targeted prescription and a physician may reasonably prefer it. A gut complaint narrows further, to BPC-157 alone.

GHK-Cu on its own is the choice when skin, hair or connective-tissue quality is the whole goal and there is no injury in the picture. GLOW adds the two repair components for someone with a soft-tissue complaint and a skin goal together.